Alfacalcidol-d7
Alfacalcidol-d7 is the deuterium labeled Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis.
For research use only. We do not sell to patients.
- Formula: C27H37D7O2
- Molecular Weight:407.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled Cas 41294-56-8
-
Molecular Weight 407.68
-
Formula C27H37D7O2
-
SMILES
C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](CCCC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C)CCC/2)[H])O)O
-
Synonyms
1-hydroxycholecalciferol-d7; 1.alpha.-Hydroxyvitamin D3-d7
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Galeşanu C, et al. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol]. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):833-41. [Content Brief]
[3]. Nuijten M, et al. Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clin Drug Investig. 2010;30(8):545-57. [Content Brief]
[4]. Shiraishi A, et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999 Oct;65(4):311-6. [Content Brief]
[5]. Nagaoka H, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res. 2014 Aug;32(8):1030-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Alfacalcidol-d7 Related Classifications
HY-10003S Related Classifications
Powered by Bioz